Sun Pharma Trails Sensex, Nifty After Six Years Amid US Woes, Regulatory Hurdles

• Sun Pharma underperforms Sensex and Nifty for the first time in six years, with its stock down 8% while benchmarks rose 9%.
• Weakness stems from softer US business, rising generics competition, pricing pressure, currency issues, and tariff uncertainty.
• Regulatory scrutiny persists, with USFDA classifying the Baska site as "Official Action Indicated" impacting key product manufacturing.
• Despite headwinds, the domestic market shows steady performance with new launches; analysts see long-term buying opportunity.
• Sun Pharma maintains a premium valuation, and 37 of 43 analysts recommend 'buy' due to intact earnings visibility.

Why It Matters: Sun Pharma faces headwinds from US business and regulatory issues but analysts see long-term value.